What is HC Wainwright's Forecast for Cibus FY2029 Earnings?

Key Points

• HC Wainwright raised its FY2029 EPS forecast for Cibus to $0.31 (from $0.27) and models FY2030 EPS of $2.12, while the consensus estimate for the current full year remains a loss of ($2.96) per share.
• In the most recent quarter Cibus reported EPS of ($0.42), beating estimates by $0.01, but revenue missed at $1.06M versus $1.64M and the company showed a very large negative net margin (3,492.3%) and negative ROE (174.58%).
• Analyst coverage is mixed (one Buy, one Hold, one Sell) with an average rating of "Hold" and an average target price of $9.00; shares trade around $1.88 with a market cap of about $102M and ~33.8% institutional ownership.

Cibus, Inc. (NASDAQ:CBUS - Free Report) - Analysts at HC Wainwright increased their FY2029 earnings estimates for shares of Cibus in a research report issued on Friday, March 27th. HC Wainwright analyst A. Dayal now expects that the company will earn $0.31 per share for the year, up from their previous estimate of $0.27. The consensus estimate for Cibus' current full-year earnings is ($2.96) per share. HC Wainwright also issued estimates for Cibus' FY2030 earnings at $2.12 EPS.

Cibus (NASDAQ:CBUS - Get Free Report) last issued its earnings results on Tuesday, March 17th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.01. Cibus had a negative net margin of 3,492.30% and a negative return on equity of 174.58%. The business had revenue of $1.06 million during the quarter, compared to analysts' expectations of $1.64 million.

CBUS has been the topic of several other reports. Canaccord Genuity Group reaffirmed a "buy" rating and set a $15.00 price objective on shares of Cibus in a research report on Monday, December 8th. Jefferies Financial Group boosted their price objective on shares of Cibus from $1.90 to $3.00 and gave the company a "hold" rating in a research report on Wednesday, March 25th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Cibus in a report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $9.00.

Cibus Price Performance

Shares of CBUS opened at $1.88 on Monday. The firm has a 50 day moving average of $2.71 and a 200 day moving average of $1.95. The company has a quick ratio of 0.72, a current ratio of 0.72 and a debt-to-equity ratio of 1.37. Cibus has a twelve month low of $1.09 and a twelve month high of $4.19. The company has a market capitalization of $102.05 million, a P/E ratio of -0.63 and a beta of 1.62.

Institutional Trading of Cibus

A number of large investors have recently added to or reduced their stakes in CBUS. Corient Private Wealth LLC purchased a new stake in shares of Cibus during the 4th quarter worth approximately $145,000. PACK Private Wealth LLC bought a new position in shares of Cibus during the 4th quarter valued at approximately $27,000. BDT Capital Partners LLC grew its holdings in shares of Cibus by 1,899.7% in the fourth quarter. BDT Capital Partners LLC now owns 63,410 shares of the company's stock valued at $110,000 after purchasing an additional 60,239 shares in the last quarter. Renaissance Technologies LLC increased its position in Cibus by 74.4% in the fourth quarter. Renaissance Technologies LLC now owns 69,400 shares of the company's stock worth $121,000 after purchasing an additional 29,600 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in Cibus by 60.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 52,364 shares of the company's stock worth $91,000 after purchasing an additional 19,717 shares during the last quarter. Institutional investors own 33.81% of the company's stock.

Cibus Company Profile

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company's platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company's core business centers on trait development services and licensing partnerships.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.